NS Pharma has initiated an exploratory clinical trial in Japan in 2019 where they found this drug to be well-tolerated after infusion of 1.62, 10, 40, and 80 mg/kg in 6 DMD boys for 24 weeks with a 10.27 % (for 40 mg/kg) and 15.79 % (for 80 mg/kg) increase in dystrophin level. This evidence concerns the gene DMD and Duchenne muscular dystrophy.